File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Implications for management of Mycobacterium tuberculosis infection in adult-to-adult live donor liver transplantation

TitleImplications for management of Mycobacterium tuberculosis infection in adult-to-adult live donor liver transplantation
Authors
KeywordsLiver transplantation
Tuberculosis
Issue Date2007
PublisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1
Citation
Liver International, 2007, v. 27 n. 1, p. 81-85 How to Cite?
AbstractBackground: Mycobacterium tuberculosis (TB) infection is a serious opportunistic infection especially in live donor liver transplantation (LDLT). Hepatotoxicity of antituberculous agents and hazardous drug interaction with immunosuppressants may render the graft more susceptible to injury. Aim of study: To review our experience of management of TB infection in liver transplant recipients including LDLT. Patients and methods: A total of 397 liver transplantations were performed in the University of Hong Kong Medical Centre from January 1991 to December 2004. Eight patients (2.0%) developed TB infection after transplantation (LDLT: n = 6, DDLT: n = 2) and their clinical courses were reviewed. Result: The mean time of developing TB infection after liver transplantation was 9 months (range 4-20 months). Anti-TB treatment was administered for a mean duration of 12.7 months (11-18 months). None of our patients developed antituberculous drug-induced hepatotoxicity or had unwanted drug interaction. With a mean follow-up of 65 months (range 18-102 months), one patient died due to the recurrence of hepatocellular carcinoma. Conclusion: High index of suspicion for TB infection should be warranted for a history of cough and fever after liver transplantation. No notable difference was observed in the natural history and management of TB infection between LDLT and DDLT. The use of antituberculous drugs is safe in liver transplant recipients provided that liver function is closely monitored and the dosage of immunosuppressants is adjusted accordingly. © 2006 Blackwell Munksgaard.
Persistent Identifierhttp://hdl.handle.net/10722/125434
ISSN
2015 Impact Factor: 4.47
2015 SCImago Journal Rankings: 1.677
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorChan, ACYen_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorNg, KKCen_HK
dc.contributor.authorChan, SCen_HK
dc.contributor.authorFan, STen_HK
dc.date.accessioned2010-10-31T11:31:12Z-
dc.date.available2010-10-31T11:31:12Z-
dc.date.issued2007en_HK
dc.identifier.citationLiver International, 2007, v. 27 n. 1, p. 81-85en_HK
dc.identifier.issn1478-3223en_HK
dc.identifier.urihttp://hdl.handle.net/10722/125434-
dc.description.abstractBackground: Mycobacterium tuberculosis (TB) infection is a serious opportunistic infection especially in live donor liver transplantation (LDLT). Hepatotoxicity of antituberculous agents and hazardous drug interaction with immunosuppressants may render the graft more susceptible to injury. Aim of study: To review our experience of management of TB infection in liver transplant recipients including LDLT. Patients and methods: A total of 397 liver transplantations were performed in the University of Hong Kong Medical Centre from January 1991 to December 2004. Eight patients (2.0%) developed TB infection after transplantation (LDLT: n = 6, DDLT: n = 2) and their clinical courses were reviewed. Result: The mean time of developing TB infection after liver transplantation was 9 months (range 4-20 months). Anti-TB treatment was administered for a mean duration of 12.7 months (11-18 months). None of our patients developed antituberculous drug-induced hepatotoxicity or had unwanted drug interaction. With a mean follow-up of 65 months (range 18-102 months), one patient died due to the recurrence of hepatocellular carcinoma. Conclusion: High index of suspicion for TB infection should be warranted for a history of cough and fever after liver transplantation. No notable difference was observed in the natural history and management of TB infection between LDLT and DDLT. The use of antituberculous drugs is safe in liver transplant recipients provided that liver function is closely monitored and the dosage of immunosuppressants is adjusted accordingly. © 2006 Blackwell Munksgaard.en_HK
dc.languageengen_HK
dc.publisherWiley-Blackwell Publishing, Inc.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=1478-3223&site=1en_HK
dc.relation.ispartofLiver Internationalen_HK
dc.rightsThe definitive version is available at www3.interscience.wiley.com-
dc.subjectLiver transplantationen_HK
dc.subjectTuberculosisen_HK
dc.subject.meshAdult-
dc.subject.meshAntitubercular Agents - pharmacokinetics - therapeutic use-
dc.subject.meshDose-Response Relationship, Drug-
dc.subject.meshOpportunistic Infections - prevention and control-
dc.subject.meshTuberculosis - diagnosis - drug therapy - transmission-
dc.titleImplications for management of Mycobacterium tuberculosis infection in adult-to-adult live donor liver transplantationen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1478-3223&volume=27&issue=1&spage=81&epage=85&date=2007&atitle=Implications+for+management+of+Mycobacterium+tuberculosis+infection+in+adult-to-adult+live+donor+liver+transplantationen_HK
dc.identifier.emailChan, ACY: acchan@hku.hken_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityChan, ACY=rp00310en_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityChan, SC=rp01568en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1478-3231.2006.01397.xen_HK
dc.identifier.pmid17241385-
dc.identifier.scopuseid_2-s2.0-33846438284en_HK
dc.identifier.hkuros175038en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33846438284&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume27en_HK
dc.identifier.issue1en_HK
dc.identifier.spage81en_HK
dc.identifier.epage85en_HK
dc.identifier.eissn1478-3231-
dc.identifier.isiWOS:000243534600012-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridChan, ACY=15828849100en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridNg, KKC=7403179075en_HK
dc.identifier.scopusauthoridChan, SC=7404255575en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.citeulike1053566-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats